Carisma Therapeutics, Inc. Stock News

Development Candidate targets Glypican-3 for the treatment of solid tumors, including hepatocellular carcinoma Nomination triggers a $2 million milestone payment to Carisma PHILADELPHIA , June 27, 202

Fast Track designation highlights potential for CT-0525 to address unmet need for patients with solid tumors Initial Phase 1 data expected by year-end 2024 PHILADELPHIA , June 25, 2024 /PRNewswire/ --

PHILADELPHIA , June 25, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing in

Meeting will be reconvened on Friday, June 14, 2024 at 10:00 a.m. Eastern Time  PHILADELPHIA , June 13, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a c

PHILADELPHIA , May 30, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing inn

CT-0525 is the first CAR-Monocyte to be evaluated in humans in the solid tumor setting Initial data expected by year-end 2024 PHILADELPHIA , May 16, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Na

Carisma Therapeutics Inc. (CARM) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $1.93 per share a year ago.

Announced CT-0525 as lead product candidate for anti-HER2 program; initial data expected by year-end 2024 Presented preclinical proof of concept data in liver fibrosis at ASGCT; expects to nominate a

Novel anti-fibrotic engineered macrophage therapy reduced liver fibrosis in preclinical models Development candidate nomination expected in the first quarter of 2025 PHILADELPHIA , May 8, 2024 /PRNews

PHILADELPHIA , May 6, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing inno

CARISMA THERAP (CARM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Industry veteran with expertise in oncology and immuno-oncology and a strong track record of advancing programs through clinical development PHILADELPHIA , May 2, 2024 /PRNewswire/ -- Carisma Therape

Preclinical data highlights the potential of engineered macrophage cell therapy as a treatment for liver and lung fibrosis Novel Redirected Soluble Modulator technology has demonstrated the potential

CARISMA THERAP (CARM) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among

PHILADELPHIA , April 3, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing in